Davie, Alison
Carter, Gebra Cuyun
Rider, Alex
Pike, James
Lewis, Katie
Bailey, Abigail
Price, Gregory L.
Ringeisen, Francois
Pivot, Xavier
Funding for this research was provided by:
Eli Lilly and Company (N/A)
Article History
Received: 25 November 2019
Accepted: 11 August 2020
First Online: 7 September 2020
Ethics approval and consent to participate
: The Advanced Breast Cancer DSP followed European Pharmaceutical Marketing Research Association guidelines [CitationRef removed] and adhered to the ICC/ESOMAR International Code on observational research [CitationRef removed]. The study protocol was reviewed and approved by the FEKI institutional review board. All patients included in the DSP provided written informed consent to participate. All data were anonymized and aggregated prior to receipt by Adelphi Real World for analysis.
: Not applicable.
: A.D., G.C.C., and G.P. have disclosed that they are employees of Eli Lilly and Company. F.R. was an employee of Eli Lilly and Company during the development of the analysis.A.B., A.R., J.P., and K.L. have disclosed that they are employees of Adelphi Real World Ltd., who own the multi-sponsored Disease Specific Programme, and were paid by Eli Lilly and Company Ltd. in the development of this analysis and manuscript.X.P. has disclosed an advisory role with Eli Lilly and Company; for which an honorarium was received from Eli Lilly and Company Ltd. for consultancy support in the development of this analysis.